- Stocks
- Pharma & Healthcare
- Rubicon Research
Rubicon Research share price
NSE: RUBICONPharma & HealthcareDrug Manufacturers - General
Rubicon Research at a glance
Rubicon Research (NSE: RUBICON) closed at ₹1,408.90 on 22 Oct 2026, down 3.57% on the day. With a market capitalisation of ₹23,956 Cr, it ranks 316th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.
At its last close the stock traded at 92.3× trailing earnings, against a return on equity of 19.1% in FY26. Its 52-week range is ₹570.75 (24 Oct 2025) to ₹1,899.00 (28 Aug 2026); the last close is 25.8% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹514 Cr (+50.7% year on year) and net profit ₹77 Cr (+111.8%), on a consolidated basis. Promoters held 59.76% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹23,956 CrRank 316 on NSE
- P/E (trailing)
- 92.3×
- Price to book
- 9.9×FY26
- EPS (TTM)
- ₹15.42to Q4 FY26
- ROE
- 19.1%FY26
- ROCE
- 24.3%FY26
- Debt to equity
- 0.2FY26
- Net profit margin
- 14.1%FY26
- Book value / share
- ₹78.07FY26
- 52-week high
- ₹1,899.0028 Aug 2026
- 52-week low
- ₹570.7524 Oct 2025
- RSI (14-day)
- 25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −3.57% | −7.1% | −18.4% | −4.3% | — |
Rubicon Research quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹317 Cr | ₹296 Cr | ₹313 Cr | ₹341 Cr | ₹352 Cr | ₹412 Cr | ₹476 Cr | ₹514 Cr |
| Revenue YoY | — | — | — | — | +11.3% | +39.2% | +51.7% | +50.7% |
| Net profit | ₹26 Cr | ₹34 Cr | ₹38 Cr | ₹36 Cr | ₹43 Cr | ₹54 Cr | ₹73 Cr | ₹77 Cr |
| Net profit YoY | — | — | — | — | +69.3% | +56.2% | +91.2% | +111.8% |
| Net margin | 8.1% | 11.6% | 12.1% | 10.6% | 12.3% | 13.1% | 15.3% | 14.9% |
| EPS | ₹1.68 | ₹2.27 | ₹2.50 | ₹2.35 | ₹2.81 | ₹3.49 | ₹4.46 | ₹4.66 |
Rubicon Research financials
| Item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹394 Cr | ₹854 Cr | ₹1,284 Cr | — |
| Operating profit | −₹11 Cr | ₹103 Cr | ₹195 Cr | — |
| Net profit | −₹17 Cr | ₹91 Cr | ₹134 Cr | — |
| EPS (₹) | −₹1.00 | ₹6.00 | ₹9.00 | — |
| Cash from operations | −₹75 Cr | ₹21 Cr | ₹159 Cr | — |
| Total debt | ₹97 Cr | ₹93 Cr | ₹64 Cr | ₹143 Cr |
| Shareholders' equity | ₹286 Cr | ₹385 Cr | ₹541 Cr | ₹1,289 Cr |
Rubicon Research shareholding pattern
| Holder | 15 Oct 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|
| Promoters | 59.99% | 59.99% | 59.86% | 59.76% |
| Foreign institutions | 9.37% | 7.99% | 7.54% | 7.52% |
| Domestic institutions | 10.54% | 9.45% | 10.02% | 9.43% |
| Non-institutions | 20.10% | 22.57% | 22.58% | 23.30% |
Rubicon Research vs peers
The listed Pharma & Healthcare companies nearest to Rubicon Research by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| KIMSKrishna Institute of Medical Sciences | ₹671.30 | +0.04% | −5.5% | ₹28,313 Cr | 111.9 | 18.0% |
| PPLPHARMAPiramal Pharma | ₹194.27 | +1.97% | +1.2% | ₹25,960 Cr | 25 | −4.0% |
| NEULANDLABNeuland Laboratories | ₹18,855.00 | −0.45% | +16.3% | ₹24,345 Cr | 66.3 | 19.4% |
| RUBICONRubicon Research | ₹1,408.90 | −3.57% | — | ₹23,956 Cr | 92.3 | 19.1% |
| PGHHProcter Gamble | ₹6,856.00 | −0.36% | −51.5% | ₹22,404 Cr | 26 | 62.3% |
| PIRPHYTOPiramal Phytoca | — | — | — | ₹21,083 Cr | — | — |
| SAGILITYSAGILITY | ₹44.78 | +1.08% | +0.9% | ₹20,790 Cr | 22.6 | 9.6% |
Ask anything about Rubicon Research
Pivot answers on the live chart with evidence you can check, and tests strategies against RUBICON's own history. Try: “Why has RUBICON moved over the last three months?” · “Backtest a 50-day moving-average crossover on RUBICON over five years” · “Compare RUBICON with KIMS on margins and valuation”
Frequently asked questions about Rubicon Research
What is the share price of Rubicon Research today?
Rubicon Research (NSE: RUBICON) last closed at ₹1,408.90 on 22 Oct 2026. Its 52-week high is ₹1,899.00 and its 52-week low is ₹570.75.
What is the market cap of Rubicon Research?
Rubicon Research's market capitalisation is ₹23,956 Cr (₹23,956 Cr) at the 22 Oct 2026 close, ranking 316th among the NSE companies Pivot tracks.
What is the P/E ratio of Rubicon Research?
Rubicon Research trades at a trailing P/E of 92.3. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 26.
What is the ROE and ROCE of Rubicon Research?
Return on equity was 19.1% in FY26 and return on capital employed was 24.3% in FY26 (consolidated figures).
Is Rubicon Research a debt-free company?
No. Rubicon Research's debt-to-equity ratio was 0.2 in FY26, with total debt of ₹143 Cr.
What were Rubicon Research's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Rubicon Research reported revenue of ₹514 Cr, +50.7% year on year, and net profit of ₹77 Cr, +111.8% year on year.
What is the shareholding pattern of Rubicon Research?
As of 30 Jun 2026: promoters 59.76%, foreign institutions 7.52%, domestic institutions 9.43%, non-institutions 23.30%.
Who are Rubicon Research's competitors?
The listed Pharma & Healthcare companies closest to Rubicon Research by market cap are Krishna Institute of Medical Sciences, Piramal Pharma, Neuland Laboratories, Procter Gamble, Piramal Phytoca and SAGILITY.
Is Rubicon Research a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Rubicon Research's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on RUBICON against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with R · all NSE stocks · this page as text